("Cyprotex" or "the Company")
Cyprotex install two AB Sciex TripleTOF® 6600
mass spectrometer systems
Cyprotex PLC (AIM:CRX), a specialist Contract Research Organisation (CRO), announced today the installation of two AB Sciex TripleTOF® 6600 mass spectrometer systems. The instruments will complement our existing Waters Xevo G2-XS QTof mass spectrometer used for high resolution accurate mass metabolite identification studies. The TripleTOF® technology has several advantages in that it generates manageable file sizes which allows more rapid data processing, and has a wider linear dynamic range to analyse concentrations over 5 orders of magnitude. These features make the system more appropriate for high throughput ADME capabilities where rapid analysis of samples from in vitro drug metabolism studies is required. One of the TripleTOF® systems features an Eksigent MicroLC liquid chromatography system at the front end, an IonDrive™ Turbo V ionisation source, and SWATH acquisition technology. The Eksigent system uses capillary flow HPLC with lower flow rates, reduced sample requirements, and improved ionisation efficiency and sensitivity. The IonDrive™ Turbo V ionisation source and SWATH acquisition technology further enhance sensitivity. These combined qualities make the system more suitable for the analysis of large molecule biotherapeutics and the detection of low levels of metabolites.
One of the TripleTOF® systems has been housed at our Macclesfield site where it will support high throughput ADME studies, eliminating the need for upfront compound optimisations required by triple quadrupole mass spectrometer systems, and the other has been housed at our new bioanalytical laboratory at the Alderley Park Biohub where it will support lower throughput metabolite identification studies and large molecule biotherapeutic analysis.
Dr Anthony Baxter, Cyprotex’s Chief Executive Officer, comments: “As we expand into new markets, our analytical capabilities need to diversify to meet the requirements for different types of molecules. Cyprotex now have an impressive range of analytical separation and detection capabilities enabling us to tackle more challenging molecules with the greatest chance of success.”
For Further Information
Tel: +44 (0) 1625 505 100
Dr Anthony Baxter, Chief Executive Office
John Dootson, Chief Financial Officer
Mark Warburton, Chief Operating Officer and Legal Counsel
Cyprotex is listed on the AIM market of the London Stock Exchange (CRX). It has sites at Macclesfield and Alderley Park, both of which are near Manchester in the UK, and at Watertown, MA and Kalamazoo, MI in the US. The Company was established in 1999 and works with more than 1500 partners within the pharmaceutical and biotech industry, cosmetics and personal care industry and the chemical industry. Cyprotex acquired Apredica and the assets of Cellumen Inc. in August 2010 and the combined business provides support for a wide range of experimental and computational ADME-Tox and PK services. The acquisition of the assets and business of CeeTox in January 2014 has enabled Cyprotex to expand its range of services to target the personal care, cosmetics and chemical industries. In 2015, Cyprotex launched its new bioscience division to expand its capabilities into phenotypic and target based screening. The Company’s core capabilities include high quality in vitro ADME services, mechanistic toxicology and high content toxicology screening services, including our proprietary CellCiphr® toxicity prediction technology, bioscience services, predictive modelling solutions including Cloe® PK, chemPK™, chemTarget and chemTox, and a range of skin, ocular and endocrine disruption services. For more information, please visit www.cyprotex.com.